Trial Profile

Phase I/IIa trial of SPL028 with psychotherapy among healthy volunteers to assess safety, tolerability, pharmacodynamics and pharmacokinetics of IM and IV administration

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SPL 028 (Primary) ; SPL 028 (Primary)
Indications Mental disorders
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Small Pharma

Most Recent Events

08 Jan 2024 According to Cybin media release, company today also announced the completion of dosing in a Phase 1 study evaluating IV and IM doses of SPL028 (deuterated DMT) in healthy participants
08 Jan 2024 Results of phase 1 part of this study published in the Cybin Media Release
04 Jan 2024 According to Cybin media release, phase 1 IM/IV SPL028 data expected early Q1 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com